The SOX6 Knockout A-375 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the A-375 human melanoma cell line, featuring targeted disruption of the SOX6 gene. This loss-of-function model enables precise investigation of SOX6-dependent biological processes in a malignant melanoma background. The knockout line serves as a robust tool for dissecting the tumor-suppressive functions attributed to SOX6 and for exploring its roles in cell differentiation, proliferation, and signal transduction.
The A-375 cell line originated from a primary malignant melanoma and is widely employed as a human skin cancer model. These melanocyte-derived tumor cells exhibit characteristic melanoma features and are frequently used in drug discovery, functional genomics, and signal transduction studies. The established genetic background of A-375 cells makes it a suitable host for evaluating the impact of SOX6 loss on melanoma cell behavior, including growth, migration, and therapeutic response.
SOX6 operates as a transcription factor downstream of TGF-beta and Wnt signaling. It is regulated by TGF-beta1/Smad3 and Wnt3a/beta-catenin; Smad3 and beta-catenin serve as key coregulators. SOX6 associates with SOX5, SOX9, beta-catenin, and Smad3 to modulate gene expression. It directly controls targets including CDKN1A, CCND1, and COL2A1, thereby influencing cell cycle arrest and differentiation. In the canonical Wnt cascade, Wnt3a activates Dvl, inhibiting GSK-3beta and stabilizing beta-catenin, which partners with TCF4, while SOX6 fine-tunes transcriptional outcomes.
In melanoma, SOX6 is considered a potential tumor suppressor whose loss may deregulate cell proliferation and differentiation. Disruption of SOX6 in A-375 cells allows researchers to model the consequences of impaired SOX6 function on melanoma progression. The knockout line can reveal how SOX6 deficiency alters the balance between cell cycle arrest and proliferation, potentially through dysregulation of CDKN1A and CCND1. Moreover, it provides a platform to study crosstalk between Wnt and TGF-beta pathways in melanocyte-derived tumor cells, shedding light on mechanisms driving tumorigenicity.
Applications encompass western blotting, RT-qPCR, cell proliferation and colony formation assays, migration/invasion studies, RNA-seq transcriptomics, ChIP-qPCR, and flow cytometric cell cycle analysis. These experiments enable dissection of SOX6??s tumor suppressor role, drug screening, and exploration of Wnt/TGF-beta crosstalk in melanoma biology. For further information, contact Ascent Research.
